An Internet Study of User’s Experiences of the Synthetic Cathinone 4-Methylethcathinone (4-MEC)

Journal of Psychoactive Drugs

Volumn 46, Issue 4, 2014, Pages 273-286

  Van Hout, Marie Claire ^a  

^a South East Technological University   (Ireland)

Author keywords

4 MEC; 4 methylethcathinone; cathinone; Internet discussion forum; mephedrone; novel psychoactive substance

Indexed keywords

4 METHYLETHCATHINONE; 4' METHYLMETHCATHINONE; CENTRAL STIMULANT AGENT; UNCLASSIFIED DRUG; 4-METHYLCATHINONE; ALKALOID; DESIGNER DRUG; METHAMPHETAMINE;

ADULT; ARTICLE; DECISION MAKING; DRUG ABUSE; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; INTERNET; MALE; OUTCOME ASSESSMENT; PERSONAL EXPERIENCE; PUBLIC OPINION; QUALITY CONTROL; WITHDRAWAL SYNDROME; AFFECT; AMPHETAMINE DEPENDENCE; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG ADMINISTRATION ROUTE; DRUG COST; DRUG EFFECTS; ECONOMICS; PSYCHOLOGY; RISK FACTOR; SYNTHESIS;

AFFECT; ALKALOIDS; AMPHETAMINE-RELATED DISORDERS; CENTRAL NERVOUS SYSTEM STIMULANTS; DESIGNER DRUGS; DRUG ADMINISTRATION ROUTES; DRUG COSTS; HUMANS; INTERNET; METHAMPHETAMINE; RISK FACTORS;

EID: 84916893400     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2014.934979     Document Type: Article

References (97)

1. Al-Habori, M. 2005.The potential adverse effects of habitual use of Catha edulis (khat). Expert Opinion on Drug Safety 4 (6): 1145–1154.
2. Aromatario, M.; Bottoni, E.; Santoni, M. & Ciallella, C. 2012. New “lethal highs”: a case of a deadly cocktail of GHB and mephedrone. Forensic Science International 223 (1–3): e38–e41.
3. Ayres, T.C. & Bond, J.W. 2012. A chemical analysis examining the pharmacology of novel psychoactive substances freely available over the internet and their impact on public (ill) health: Legal highs or illegal highs? BMJ Open. doi:10.1136/bmjopen-2012-000977
4. Babbie, E.R. 2010. The Practice of Social Research, 12th ed. Wadsworth: Cengage Learning.
5. Bajaj, N.; Mullen, D. & Wylie, S. 2010. Dependence and psychosis with 4-methylmethcathinone (mephedrone) use. British Medical Journal Case Reports. doi:10.1136/bcr.02.2010.2780
6. Brandt, S.D.; Sumnall, H.R.; Measham, F. & Cole, J. 2010a. Analyses of second-generation “legal highs” in the UK: Initial findings. Drug Testing and Analysis 2 (8): 377–382.
7. Brandt, S.D.; Sumnall, H.R.; Measham, F. & Cole, J. 2010b. Second generation mephedrone: The confusing case of NRG-1. British Medical Journal 341: c3564.
8. Brandt, S.D.; Freeman, S.; Sumnall, H.R.; Measham, F. & Cole, J. 2010c. Analysis of NRG legal highs in the UK: Identification and formation of novel cathinones. Drug Testing and Analysis 3 (9): 569–575.
9. Brauser, D. 2012. Injection of “bath salts” linked to necrotizing fasciitis. Orthopedics 35 (1): 124–127.
10. Brennan, R. & Van Hout, M.C. 2012. Miaow miaow: A review of the new psychoactive drug Mephedrone. Drugs and Alcohol Today 12 (4): 241–253.
11. Bruno, R.; Matthews, A.J.; Dunn, M.; Alati, R.; McIlwraith, F.; Hickey, S.; Burns, L. & Sindicich, N. 2011. Emerging psychoactive substance use among regular ecstasy users in Australia. Drug and Alcohol Dependence 124 (1–2): 19–25.
12. Brunt, T.M.; Poortman, A.; Niesink, R.J. & van den Brink, W. 2010. Instability of the ecstasy market and a new kid on the block: Mephedrone. Journal of Psychopharmacology 25 (11): 1543–1547.
13. Burillo-Putze, G.; Dominguez-Rodriguez, A.; Abreu-Gonzalez, P. & Nogue Xarau, S. 2011. Khat, mephedrone & chest pain. Medicina Clínica (Barc) 137 (15): 712–3.
14. Capriola, M. 2013. Synthetic cathinone abuse. Clinical Pharmacology: Advances and Applications 5 (1): 109–115.
15. Carhart-Harris, R.L.; King, L.A. & Nutt, D. 2011. A web-based survey on mephedrone. Drug and Alcohol Dependence 118 (1): 19–22.
16. Coppola, M. & Mondola, R. 2012. Synthetic cathinones: Chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as “bath salts” or “plant food.” Toxicology Letters 211 (2): 144–149.
17. Corazza, O.; Demetrovics, Z.; van den Brink, W. & Schifano, F. 2013. “Legal highs” an inappropriate term for “novel psychoactive drugs” in drug prevention and scientific debate. International Journal of Drug Policy 24 (1): 82–83.
18. Corkery, J.M.; Schifano, F. & Ghodse, A.H. 2012. Mephedrone-related fatalities in the United Kingdom: Contextual, clinical and practical issues. In L. Gallelli (Ed.) Pharmacology. Croatia: In Tech.
19. Dargan, P.I.; Albert, S. & Wood, D.M. 2010. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 103 (11): 875–879.
20. Dargan, P.I.; Sedefov, R.; Gallegos A. & Wood D.M. 2011. The pharmacology and toxicology of the synthetic cathinonemephedrone (4-methylmethcathinone). Drug Testing and Analysis 3 (7–8): 454–63.
21. Dargan, P.I. & Wood, D.M. 2010. Annex 1 to the risk assessment report: technical report on mephedrone. Available at: http://www.ofdt.fr/BDD/publications/docs/rarOEDTmephAnn1.pdf. Accessed May 20, 2011.
22. Davey, Z.; Corazza, O.; Schifano, F.; Deluca, P. & Psychonaut Web Mapping Group. 2010. Mass-information: Mephedrone, myths, and the new generation of legal highs. Drugs and Alcohol Today 10: 24–28.
23. Davies, S.; Wood, D.M.; Smith, G.; Button, J.; Ramsey, J.; Archer, R.; Holt, D.W. & Dargan, P.I. 2010. Purchasing “legal highs” on the Internet: Is there consistency in what you get? QJM 103 (7): 489–493.
24. Deluca, P.; Davey, Z.; Corazza, O.; Di Furia, L.; Farre, M.; Flesland, L.H.; Mannonen, M.; Majava, A.; Peltoniemi, T.; Pasinetti, M.; Pezzolesi, C.; Scherbaum, N.; Siemann, H.; Skutle, A.; Torrens, M.; van der Kreeft, P.; Iversen, E. & Schifano, F. 2012. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Progress in Neuro-psychopharmacology and Biological Psychiatry 39 (2): 221–226.
25. Deluca, P.; Schifano, F. & the Psychonaut 2002 Research Group. 2007. Searching the Internet for drug related websites: Analysis of online available information on ecstasy (MDMA). American Journal on Addictions 26 (2): 479–83.
26. Deluca, P.; Schifano, F.; Davey, Z.; Corazza, O.; Di Furia, L. & The Psychonaut Web Mapping Research Group. 2009. Mephedrone Report. London: Institute of Psychiatry, Kings College.
27. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). 2010. Annual Report 2010. Available at: http://www.emcdda.europa.eu/publications/annualreport. Accessed May 20, 2012.
28. Europol—EMCDDA. 2010a. Joint Report on a New Psychoactive Substance: 4-Methylmethcathinone (Mephedrone), Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
29. Europol—EMCDDA. 2010b. Risk Assessment of New Psychoactive Substances—Operating Guidelines. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
30. Fantegrossi, W.E.; Gannon, B.M.; Zimmerman, S.M. & Rice, K.C. 2013. In vivo effects of abused “bath salt” constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: Drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology 38 (4): 563–73.
31. Fass, J.A.; Fass, A.D. & Garcia, A.S. 2012. Synthetic cathinones (bath salts): Legal status and patterns of abuse. The Annals of Pharmacotherapy 46 (3): 436–41.
32. Fielding, N.G.; Lee, R.M. & Blank, G. (Eds.). 2008. The Handbook of Online Research Methods. London: Sage.
33. Forsyth, A.J.M. 2012. Virtually a drug scare: Mephedrone and the impact of the Internet on drug news transmission International Journal of Drug Policy 23 (3): 198–209.
34. Freeman, T.P.; Morgan, C.; Vaughn-Jones, J.; Hussain, N.; Karimi, K. & Curran, V. 2012. Cognitive and subjective effects of mephedrone and factors influencing use of a “new legal high.” Addiction 107 (4): 792–800.
35. Gallagher, C.T.; Assi, S.; Stair, J.L.; Fergus, S.; Corazza, O; Corkery, J.M. & Schifano, F. 2012. 5,6-Methylenedioxy-2-aminoindane: From laboratory curiosity to “legal high.” Human Psychopharmacology 27 (2): 106–12.
36. German, C.L.; Fleckenstein, A.E. & Hanson, G. 2013. Bath salts and synthetic cathinones: An emerging designer drug phenomenon. Life Sciences 97 (1): 2–8.
37. Gil, D.; Adamowicz, P.; Skulska, A.; Tokarczyk, B. & Stanaszek, R. 2013. Analysis of 4-MEC in biological and non-biological material: Three case reports. Forensic Science International 228 (1–3): e11–5.
38. Gustavsson, D. & Escher, C. 2009. Mephedrone—Internet drug which seems to have come and stay: Fatal cases in Sweden have drawn attention to previously unknown substances. Lakartidningen 106 (43): 2769–2777.
39. Hadlock, G.C.; Webb, K.M.; McFadden, L.M.; Wen Chu, P.; Ellis, J.D.; Allen, S.C.; Andrenyak, D.M.; Vieira-Brock, P.L.; German, C.L.; Conrad, K.M.; Hoonakker, A.J.; Gibb, J.W.; Wilkins, D.G.; Hanson, G.R. & Fleckenstein, A.E. 2011. 4-Methylmethcathinone (mephedrone): Neuropharmacological effects of a designer stimulant of abuse. Journal of Pharmacology and Experimental Therapeutics 339 (2): 530–6.
40. Hassan, N.A.; Gunaid, A.A. & Murray-Lyon, I. 2007. Khat (Catha edulis): Health aspects of khat chewing. East Mediterranean Health Journal 13 (3): 706–718.
41. Hill, S. & Thomas, S.H. 2011. Clinical toxicology of newer recreational drugs. Clinical Toxicology 49 (8): 705–19.
42. Holsti, O.R. 1969. Content Analysis for the Social Sciences and Humanities. Reading, MA: Addison-Wesley.
43. Iversen, L.; Gibbons, S.; Treble, R.; Setola, V.; Ping Huang, X. & Roth, B. 2013. Neuropharmacology and analgesia neurochemical profiles of some novel psychoactive substances European Journal of Pharmacology 700 (1–3): 147–151.
44. James, D.; Adams, R.D.; Spears, R.; Cooper, G.; Lupton, D.J. & Thompson, J.P. 2010. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emergency Medicine Journal 28 (8): 686–9.
45. James, D.; Adams, R.D.; Spears, R.; Cooper, G.; Lupton, D.J.; Thompson, J.P.; Thomas, S.H. & the National Poisons Information Service. 2011. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emergency Medical Journal 28 (8): 686.
46. Jankovics, P.; Váradi, A.; Tölgyesi, L.; Lohner, S.; Németh-Palotás, J. & Koszegi-Szalai, H. 2011. Identification and characterization of the new designer drug 4′-methylethcathinone (4-MEC) and elaboration of a novel liquid chromatography–tandem mass spectrometry (LC–MS/MS) screening method for seven different methcathinone analogs. Forensic Science International 210: 213–20.
47. Jankovics, P.; Váradi, A.; Tölgyesi, L.; Lohner, S.; Németh-Palotás, J. & Koszegi-Szalai, H. 2013. Recreational use of 1-(2-naphthyl)-2-(1-pyrrolidinyl)-1-pentanone hydrochloride (NRG-1), 6-(2-aminopropyl) benzofuran (Benzofury/ 6-APB) and NRG-2 with review of available evidence-based literature. Human Psychopharmacology 28 (4): 356–64.
48. Jones, A.L. 2010. Legal “highs” available through the Internet: Implications and solutions? Quarterly Journal of Medicine 103 (7): 535–6.
49. Kasick, D.P.; McKnight, C.A. & Klisovic, E. 2012. Bath salt ingestion leading to severe intoxication delirium: Two cases and a brief review of the emergence of mephedrone use. The American Journal of Drug and Alcohol Abuse 38 (2): 176–80.
50. Kelly, J.P. 2011. Cathinone derivatives: A review of their chemistry, pharmacology and toxicology. Drug Testing and Analysis. 3 (7–8): 439–453.
51. Khreit, O.; Irving, C.; Schmidt, E.; Parkinson, J.; NicDaeid, N. & Sutcliffe, O. 2012. Synthesis, full chemical characterisation and development of validated methods for the quantification of the components found in the evolved “legal high” NRG-2. Journal of Pharmaceutical and Biomedical Analysis 61: 122– 135.
52. Kjellgren, A.; Henningsson, H. & Soussan, C. 2013. Fascination and social togetherness: Discussions about spice smoking on a Swedish Internet forum. Substance Abuse 27 (7): 191–8.
53. Kjellgren, A. & Jonsson, K. 2013. Methoxetamine (MXE): A Phenomenological Study of Experiences Induced by a “Legal High” from the Internet. Journal of Psychoactive Drugs 45 (3): 276–286.
54. Kjellgren, A. & Soussan, C. 2011. Heaven and hell: A phenomenological study of recreational use of 4-HO-MET in Sweden. Journal of Psychoactive Drugs 43 (3): 211–9.
55. Lusthof, K.J.; Oosting, R.; Maes, A.; Verschraagen, M.; Dijkhuizen, A. & Sprong, A.G. 2011. A case of extreme agitation and death after the use of mephedrone in The Netherlands. Forensic Science International 206 (1–3): 93–5.
56. Mackay, K.; Taylor, M. & Bajaj, N. 2011. The adverse consequences of mephedrone use: A case series. The Psychiatrist 35: 203–5.
57. Marinetti, L.J. & Antonides, H.M. 2013. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: Method development, drug distribution and interpretation of results. Journal of Analytical Toxicology 37(3): 135–46.
58. Martínez-Clemente, J.; Escubedo, E.; Pubill, D. & Camarasa, J. 2011. Interaction of mephedrone with dopamine and serotonin targets in rats. European Neuropsychopharmacology 22 (3): 231–6.
59. Maskell, P.D.; De Paoli, G.; Seneviratne, C. & Pounder, D.J. 2011. Mephedrone (4-methyl-methcathinone)-related deaths. Journal of Analytical Toxicology 35 (3): 188–91.
60. Mayer, M.; Benko, A.; Huszar, A.; Sipos, K.; Lajtai, A.; Lakatos, A. & Porpaczy, Z. 2012. Simultaneous determination of 4-substituted cathinones (4-MMC, 4-MEC and 4-FMC) in human urine by HPLC–DAD. Journal of Chromatographic Science 2: 1–6.
61. McElrath, K. & O’Neill, C. 2011. Experiences with mephedrone pre- and post-legislative controls: Perceptions of safety and sources of supply. International Journal of Drug Policy 22 (2): 120–127.
62. McElrath, K. & van Hout, M.C. 2011. A preference for mephedrone: Drug markets, drugs of choice and the emerging “legal high” scene. Journal of Drug Issues 41 (4): 487–507.
63. Measham, F.; Moore, K.; Newcombe, R. & Welch, Z. 2010. Tweaking, bombing, dabbing, and stockpiling: The emergence of mephedrone and the perversity of prohibition. Drugs and Alcohol Today 10 (1): 14–21.
64. Measham, F.; Moore, K. & Østerguard, J. 2011. Mephedrone, “bubble” and unidentified white powders: The contested identities of synthetic “legal highs.” Drugs and Alcohol Today 11 (3): 137–46.
65. Miller P.G. & Sønderlund, A.L. 2010. Using the internet to research hidden populations of illicit drug users: A review. Addiction 105 (9): 1557–67.
66. Morris, K. 2010. UK places generic ban on mephedrone drug family. The Lancet 375 (9723): 1333–4.
67. Newcombe, R. 2008. Ketamine case study: The phenomenology of a ketamine experience. Addiction Research and Theory 16 (3): 209–15.
68. Omer, T.A. & Doherty, C. 2011. Posterior reversible encephalopathy syndrome (PRES) complicating the “legal high” mephedrone. British Medical Journal Case Reports. doi: 10.1136/bcr.02.2011.3904.
69. Prosser, J.M. & Nelson, L.S. 2011. The toxicology of bath salts: A review of synthetic cathinones. Journal of Medical Toxicology 8 (1): 33–42.
70. Regan, L.; Mitchelson, M. & MacDonald, C. 2011. Mephedrone toxicity in a Scottish emergency department. Emergency Medicine Journal 28 (12): 1055–8.
71. Robinson, J.E.; Agoglia, A.E.; Fish, E.W.; Krouse, M.C. & Malanga, C.J. 2012. Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL/6 J 796 mice: Comparison to cocaine. Behavioural Brain Research 234 (1): 76–81.
72. Rojek, S.; Kłys, M.; Maciów, M.; Kula, K. & Strona, M. 2012. Two fatal cases of intoxication with 4-MMC and 4-MEC: Medico legal expertise. Presented at the Annual Meeting of the International Association of Forensic Toxicologists, 4 June 2012, Hamamatsu, Japan.
73. Schifano, F.; Albanese, A.; Fergus, S.; Stair, J.L.; Deluca, P.; Corazza, O.; Davey, Z.; Corkery, J.; Siemann, H.; Scherbaum, N.; Farre, M.; Torrens, M.; Demetrovics, Z.; Ghodse, A.H.; Psychonaut Web Mapping & ReDNet Research Groups. 2011. Mephedrone (4-methylmethcathinone; “meow meow”): Chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 214 (3): 593–602.
74. Schifano, F.; Corkery, J. & Ghodse, A.H. 2012. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, ‘‘meow meow’’) in the United Kingdom. Journal of Clinical Psychopharmacology 32 (5): 710–714.
75. Schmidt, M.M.; Sharma, A.; Schifano, F. & Feinmann, C. 2010. ‘‘Legal highs’’ on the net: Evaluation of UK-based websites, products and product information. Forensic Science International 206 (1–3): 92–97.
76. Shulgin, A.; Shulgin, A. & Jacob, P. 1986. A protocol for the evaluation of new psychoactive drugs in man. Methods and Findings in Experimental Clinical Pharmacology 8 (5): 313–320.
77. Solberg, U. 2012. Websites as a source of new drugs/“legal highs.” Recreational Drugs European Network (RedNet News), 8 February. www.rednetproject.eu/documents/newsletters/Rednet_News_FEB12.pdf.
78. Spiller, H.A.; Ryan, M.L.; Weston, R.G. & Jansen, J. 2011. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clinical Toxicology 49 (6): 499–505.
79. Torrance, H. & Cooper, G. 2010. The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Science International 202 (1–3): e62–e63.
80. Urban, M.; Rudecki, T.; Wroblewski, D. & Rabe-Jablonska, J. 2011. Psychotic disorders related with chronic use of mephedrone: Case report. Psychiatria Polska 45 (3): 431–7.
81. Van Hout, M.C. & Bingham, T. 2012. A costly turn on: Patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. International Journal of Drug Policy 23 (3): 188–97.
82. Van Hout, M.C. & Brennan, R. 2011a. Plant food for thought: A qualitative study of mephedrone use in Ireland. Drugs: Education, Prevention and Policy 18 (5): 371–81.
83. Van Hout, M.C. & Brennan, R. 2011b. Heads held high: An exploratory study of legal highs in pre-legislation Ireland. Journal of Ethnicity of Substance Abuse 10 (3): 256–72.
84. Van Hout, M.C. & Brennan, R. 2011c. Bump and grind: An exploratory study of mephedrone users’ perceptions of sexuality and sexual risk. Drugs and Alcohol Today 11 (2): 93–103.
85. Van Hout, M.C. & Brennan, R. 2012. Curiosity killed M-Cat: A post-legislative study on mephedrone use in Ireland. Drugs: Education, Prevention and Policy 19 (2): 156–62.
86. Vardakou, I.; Pistos, C. & Piliopoulou, C.H. 2011. Drugs for youth via internet and the example of mephedrone. Toxicology Letters 201 (3): 191–5.
87. Walsh, C. 2011. Drugs, the internet and change. Journal of Psychoactive Drugs 43 (1): 55–63.
88. Watterson, L.R.; Kufahl, P.R.; Nemirovsky, N.E.; Sewalia, K.; Grabenauer, M.; Thomas, B.F.; Marusich, J.A.; Wegner, S. & Olive, M.F. 2012. Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addiction Biology 19 (2): 165–74.
89. Winstock, A.R.; Marsden, J. & Mitcheson, I. 2010.What should be done about mephedrone. British Medical Journal 340: c1605.
90. Winstock, A.R. & Mitcheson, L. 2012. New recreational drugs and the primary care approach to patients who use them. British Medical Journal 344: e288.
91. Winstock, A.R.; Mitcheson, L.R.; Deluca, P.; Davey, Z.; Corazza, O. & Schifano, F. 2011a. Mephedrone, new kid for the chop? Addiction 106: 154–61.
92. Winstock, A.R.; Mitcheson, L.R.; Ramsey, J.; Davies, S.; Puchnarewicz, M. & Marsden, J. 2011b. Mephedrone: Use, subjective effects and health risks. Addiction 106 (11): 1991–1996.
93. Wong, M.L. & Holt, R.I. 2011. The potential dangers of mephedrone in people with diabetes: A case report. Drug Testing and Analysis 3 (7–8): 464–5.
94. Wood, D., & Dargan, P. 2012. Mephedrone (4-methylmethcathinone): What is new in our understanding of its use and toxicity. Progress in Neuro-Psychopharmacology & Biological Psychiatry 39 (2): 227–233.
95. Wood, D.M.; Greene, S.L. & Dargan, P.I. 2010. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emergency Medicine Journal 28 (4): 280–282.
96. Zawilska, J. & Wojcieszak, J. 2013. Designer cathinones—An emerging class of novel recreational drugs. Forensic Science International 231 (1–3): 42–53.
97. Zuba, D. & Byrska, B. 2013. Prevalence and co-existence of active components of “legal highs.” Drug Testing and Analysis 5 (6): 420–9.